New York, NY, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Viral Vectors and Plasmid DNA Manufacturing Market by Product Type (Viral Vectors (Retrovirus, Lentiviruses, Adenoviruses, Adeno-Associated Viruses, and Others) and Plasmid (DNA Conjugative Plasmids, and Non-Conjugative Plasmids)), by Application (Gene and Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, and Others), and by End-User (Biotechnology Companies, Research Institutes, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2026”. According to the report, the global viral vectors and plasmid DNA manufacturing market was valued at approximately USD 340 million in 2017 and is expected to generate revenue of around USD 1860 million by 2026, growing at a CAGR of around 20% between 2018 and 2026.
The viral vectors and plasmid DNA manufacturing normally comprises the use of panomics and system biology to regulate the source of a patient's disease at the molecular stage along with the use of determined medicines to address the patient's disease. Furthermore, viral vectors and plasmid DNA help in reducing the price of management and support to decrease the recurrent medication dosage. The growing prevalence of life-threatening diseases, such as cancer, rising geriatric population, and the growing demand for personalized medicines are anticipated to propel the viral vectors and plasmid DNA manufacturing market in the future. Moreover, increasing government grants and initiatives and rising funding by private players for research and developments activities in the viral vectors and plasmid DNA manufacturing are anticipated to further drive this market over the forecast timeframe.
Browse through 72 Tables & 21 Figures spread over 120 Pages and in-depth TOC on “Global Viral Vectors and Plasmid DNA Manufacturing Market: Industry Type, Size, Share, Trends and Forecast 2016 – 2022”.
Request Free Sample Report of Global Viral Vectors and Plasmid DNA Manufacturing Market Report @ https://www.zionmarketresearch.com/sample/viral-vectors-and-plasmid-dna-manufacturing-market
The viral vectors and plasmid DNA manufacturing market are fragmented into product type, application, and end-user. By product type, this market is segmented into viral vectors and plasmid. The viral vectors are further segmented into a retrovirus, lentiviruses, adenoviruses, adeno-associated viruses, and others. The plasmid segment includes DNA conjugative plasmids and non-conjugative plasmids. Viral vectors held the largest share, i.e., 80%, in the market globally in 2017. It is also expected to register a growth rate of around 21% over the forecast time period. Adeno-associated viruses held more than 30% in 2017 in this global market. Alternatively, lentiviruses are likely to register A CAGR of 27.3% from 2018 to 2026, owing to their rising application in cancer treatment.
By application, the viral vectors and plasmid DNA manufacturing market for viral vectors and plasmid DNA manufacturing are segmented into gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The gene and cancer therapies held a 70% share of the global market, due to the rising prevalence of cancer. Immunotherapy is expected to register a significant CAGR in the future, due to the development of newer drugs.
Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/viral-vectors-and-plasmid-dna-manufacturing-market
By end-user, the market is segmented into biotechnology companies, research institutes, hospitals, and others. Research institutes held the largest market share in 2017 globally, due to the increasing research and development activates for various chronic diseases, such as cancer. In terms of growth rate, biopharmaceutical companies are estimated to register good growth in this global market, owing to the increased spending on R&D.
By geography, the viral vectors and plasmid DNA manufacturing market is divided into Asia Pacific, Europe, North America, Latin America, and the Middle East and Africa. In terms of revenue share, North America held the largest share, i.e., around 40%, in the global market. It is expected to grow significantly over the forecast time period, due to a large number of research institutes, growing government support for research activities, surging incidences of chronic diseases, and increasing geriatric population. According to the statistics published by the American Cancer Society, in the U.S., cancer is the second most common reason for death. As per the World Health Organization, worldwide, there were 14 million new cancer cases in 2012 and 8.8 million cancer-related deaths in 2015. Globally, nearly 1 in 6 deaths is caused by cancer. According to the World Health Organization, the number of people 60 years or above would double by 2050, i.e., growing from 962 million globally in 2017 to 2.1 billion in 2050. Gene therapy provides prominent treatment options for a wide variety of diseases, which includes cancer, viral infections, and inherited disorders. Thus, the viral vectors and plasmid DNA manufacturing market is likely to be further boosted by a large patient pool and the need for significant medical treatment over the projected timeframe.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/viral-vectors-and-plasmid-dna-manufacturing-market
Asia Pacific is anticipated to register a high CAGR in the global viral vectors and plasmid DNA manufacturing market in the upcoming years. The growing government initiatives and grants and increased investments by private companies related to R&D activities are likely to fuel this regional market. To overcome the challenge of manufacturing, prominent quality vectors in terms of formulation, cost physical size and formulation, manufacturers are adopting various advanced techniques, such as the development of cell line culture, expression systems, cell culture system, and current good manufacturing practices. Additionally, grants provided by governments and ruling authorities and the involvement of prominent market players in the research and development activities for product advancement is estimated to drive the region’s viral vectors and plasmid DNA manufacturing market over the estimated timeframe.
Latin America and the Middle East and Africa hold the least share in the market but are expected to register a significant CAGR in the viral vectors and plasmid DNA manufacturing market in the future. This can be attributed to the growing viral and non-viral vector applications and increasing awareness about vector products among the population. Surging investments made in drug development and commercialization of viral vectors and plasmid DNA manufacturing is mainly driven by the emphasis on the commercial grade products, which can be used for delivering high doses of biopharmaceutical drugs and can provide significant gene therapy. Additionally, gene therapy being more advanced as compared to conventional techniques is further attracting the developing regions toward the adoption of comparatively more prominent, advanced, and suitable techniques. This is estimated to further drive the viral vectors and plasmid DNA manufacturing market in developing countries in the upcoming years.
Browse the full "Viral Vectors and Plasmid DNA Manufacturing Market by Product Type (Viral Vectors (Retrovirus, Lentiviruses, Adenoviruses, Adeno-Associated Viruses, and Others) and Plasmid (DNA Conjugative Plasmids, and Non-Conjugative Plasmids)), by Application (Gene and Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, and Others), and by End-User (Biotechnology Companies, Research Institutes, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2026" Report At https://www.zionmarketresearch.com/report/viral-vectors-and-plasmid-dna-manufacturing-market
Some key players of the viral vectors and plasmid DNA manufacturing market are Vigene Biosciences Inc., Lonza, FinVector Vision Therapies, Kaneka Corporation (Eurogentec), VGXI, Inc., VIROVEK, SIRION Biotech GmbH, Cobra Biologics, Novasep, FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc., Genzyme Corporation, ALDEVRON, Brammer Bio, Oxford Gene Technology, and General Electric Company (GE Healthcare), among others.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/3664
This report segments the global viral vectors and plasmid DNA manufacturing market into:
Global Viral Vectors and Plasmid DNA Manufacturing Market: Product Type Analysis
- Viral Vectors
- Retrovirus
- Lentiviruses
- Adenoviruses
- Adeno-Associated Viruses
- Others
- Plasmids
- DNA Conjugative Plasmids
- Non-Conjugative Plasmids
Global Viral Vectors and Plasmid DNA Manufacturing Market: Application Analysis
- Gene and Cancer Therapies
- Viral Infections
- Immunotherapy
- Formulation Development
- Others
Global Viral Vectors and Plasmid DNA Manufacturing Market: End-User Analysis
- Biopharmaceutical Companies
- Research Institutes
- Others
Global Viral Vectors and Plasmid DNA Manufacturing Market: Regional Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Cancer Biomarkers Market: https://www.zionmarketresearch.com/report/cancer-biomarkers-market
- CRISPR Genome Editing Market: https://www.zionmarketresearch.com/report/crispr-genome-editing-market
- Cell Expansion Market: https://www.zionmarketresearch.com/report/cell-expansion-market
- Organ preservation Market: https://www.zionmarketresearch.com/report/organ-preservation-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Blog: http://usindustrynews.com | http://europeindustrynews.com | http://zmrresearchnews.us | http://zmrnewsanalysis.com
Contact Us:
Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com
Blog: http://zmrblog.com